{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:09:23Z","timestamp":1778101763272,"version":"3.51.4"},"reference-count":241,"publisher":"Portland Press Ltd.","issue":"4","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":265,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,12,21]]},"abstract":"<jats:p>Challenges in the management of ocular pain are an underappreciated topic. Currently available therapeutics lack both efficacy and clear guidelines for their use, with many also possessing unacceptable side effects. Promising novel agents would offer analgesic, anti-inflammatory, and possibly neuroprotective actions; have favorable ocular safety profiles; and show potential in managing neuropathic pain. Growing evidence supports a link between the endocannabinoid system (ECS) and a range of physiological and disease processes, notably those involving inflammation and pain. Both preclinical and clinical data suggest analgesic and anti-inflammatory actions of cannabinoids and ECS-modifying drugs in chronic pain conditions, including those of neuropathic origin. This review will examine existing evidence for the anatomical and physiological basis of ocular pain, specifically, ocular surface disease and the development of chronic ocular pain. The mechanism of action, efficacy, and limitations of currently available treatments will be discussed, and current knowledge related to ECS-modulation of ocular pain and inflammatory disease will be summarized. A perspective will be provided on the future directions of ECS research in terms of developing cannabinoid therapeutics for ocular pain.<\/jats:p>","DOI":"10.1042\/ns20170144","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T16:34:35Z","timestamp":1540226075000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options"],"prefix":"10.1042","volume":"2","author":[{"given":"J.\u00a0Daniel","family":"Lafreniere","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Dalhousie University, Halifax, NS, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie\u00a0E.M.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Dalhousie University, Halifax, NS, Canada"},{"name":"Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada"},{"name":"Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, NS, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"key":"2021111608021201600_B1","article-title":"Anatomy","volume-title":"The Ocular Circulation","author":"Kiel","year":"2010"},{"key":"2021111608021201600_B2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.clindermatol.2014.10.006","article-title":"Human ocular anatomy","volume":"33","author":"Kels","year":"2015","journal-title":"Clin. Dermatol."},{"key":"2021111608021201600_B3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0079-6123(05)51002-1","article-title":"Biological organization of the extraocular muscles","volume":"151","author":"Spencer","year":"2006","journal-title":"Prog. Brain Res."},{"key":"2021111608021201600_B4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3390\/jfb6030917","article-title":"Substrates for expansion of corneal endothelial cells towards bioengineering of human corneal endothelium","volume":"6","author":"Navaratnam","year":"2015","journal-title":"J. Funct. Biomater."},{"key":"2021111608021201600_B5","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.5301\/EJO.2010.6049","article-title":"Blood-retinal barrier","volume":"21","author":"Cunha-Vaz","year":"2011","journal-title":"Eur. J. Ophthalmol."},{"key":"2021111608021201600_B6","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jcrs.2010.12.037","article-title":"Anatomy and physiology of the cornea","volume":"37","author":"DelMonte","year":"2011","journal-title":"J. Cataract Refract. Surg."},{"key":"2021111608021201600_B7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.exer.2003.09.023","article-title":"Neural basis of sensation in intact and injured corneas","volume":"78","author":"Belmonte","year":"2004","journal-title":"Exp. Eye Res."},{"key":"2021111608021201600_B8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/bjophthalmol-2014-306280","article-title":"Ocular neuropathic pain","volume":"100","author":"Rosenthal","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"2021111608021201600_B9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0014-4835(03)00050-2","article-title":"Corneal nerves: structure, contents and function","volume":"76","author":"M\u00fcller","year":"2003","journal-title":"Exp. Eye Res."},{"key":"2021111608021201600_B10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1350-9462(96)00027-4","article-title":"Neurobiology of ocular pain","volume":"16","author":"Belmonte","year":"1997","journal-title":"Prog. Ret. Eye Res."},{"key":"2021111608021201600_B11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1469-7580.2005.00428.x","article-title":"From nociception to pain perception: imaging the spinal and supraspinal pathways","volume":"207","author":"Brooks","year":"2005","journal-title":"J. Anat."},{"key":"2021111608021201600_B12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S1542-0124(12)70112-X","article-title":"Nerves and sensations from the eye surface","volume":"2","author":"Belmonte","year":"2004","journal-title":"Ocul. Surf."},{"key":"2021111608021201600_B13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum","year":"2009","journal-title":"Cell"},{"key":"2021111608021201600_B14","first-page":"985","article-title":"Architecture of human corneal nerves","volume":"38","author":"M\u00fcller","year":"1997","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2021111608021201600_B15","first-page":"472","article-title":"The perception of pain","volume-title":"Principles of Neuroscience","author":"Basbaum","year":"2000"},{"key":"2021111608021201600_B16","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1212\/WNL.0000000000001382","article-title":"Ion channels in nociceptors: recent developments","volume":"84","author":"Benarroch","year":"2015","journal-title":"Neurology"},{"key":"2021111608021201600_B17","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1152\/jn.2000.84.2.1050","article-title":"Cornea-responsive medullary dorsal horn neurons: modulation by local opioids and projections to thalamus and brain stem","volume":"84","author":"Hirata","year":"2000","journal-title":"J. Neurophysiol."},{"key":"2021111608021201600_B18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.exer.2009.11.018","article-title":"Distinct central representations for sensory fibers innervating either the conjunctiva or cornea of the rat","volume":"90","author":"Panneton","year":"2010","journal-title":"Exp. Eye Res."},{"key":"2021111608021201600_B19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neuroscience.2012.11.033","article-title":"Corneal afferents differentially target thalamic- and parabrachial-projecting neurons in spinal trigemina nucleus caudalis","volume":"232","author":"Aicher","year":"2013","journal-title":"Neuroscience"},{"key":"2021111608021201600_B20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40135-015-0073-9","article-title":"What causes eye pain?","volume":"3","author":"Belmonte","year":"2015","journal-title":"Curr. Ophthalmol. Rep."},{"key":"2021111608021201600_B21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/08820538.2015.1114853","article-title":"Understanding neuropathic corneal pain\u2014 gaps and current therapeutic approaches","volume":"31","author":"Goyal","year":"2016","journal-title":"Sem. Ophthalmol."},{"key":"2021111608021201600_B22","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/bjo.2009.173799","article-title":"Architecture and distribution of human corneal nerves","volume":"94","author":"Al-Aqaba","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"2021111608021201600_B23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/01.ico.0000154384.05614.8f","article-title":"Epithelial innervation of human cornea: a three-dimensional study using confocal laser scanning fluorescence microscopy","volume":"24","author":"Guthoff","year":"2005","journal-title":"Cornea"},{"key":"2021111608021201600_B24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.brainres.2006.02.035","article-title":"Peripheral and central distribution of TRPV1, substance P and CGRP of rat corneal neurons","volume":"1085","author":"Murata","year":"2006","journal-title":"Brain Res."},{"key":"2021111608021201600_B25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/jcp.21141","article-title":"Transient receptor potential vanilloid 1 activation induces inflammatory cytokine release in corneal epithelium through MAPK signaling","volume":"213","author":"Zhang","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"2021111608021201600_B26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.exer.2004.09.012","article-title":"EGF suppresses hydrogen peroxide induced Ca2+ influx by inhibiting L-type channel activity in cultured human corneal endothelial cells","volume":"80","author":"Mergler","year":"2005","journal-title":"Exp. Eye Res."},{"key":"2021111608021201600_B27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.exer.2010.03.010","article-title":"TRPV channels mediate temperature-sensing in human corneal endothelial cells","volume":"90","author":"Mergler","year":"2010","journal-title":"Exp. Eye. Res."},{"key":"2021111608021201600_B28","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1002\/jcp.22514","article-title":"Thermosensitive transient receptor potential channels in human corneal epithelial cells","volume":"226","author":"Mergler","year":"2011","journal-title":"J. Cell Physiol."},{"key":"2021111608021201600_B29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000365334","article-title":"Temperature-sensitive transient receptor potential channels in corneal tissue layers and cells","volume":"52","author":"Mergler","year":"2014","journal-title":"Ophthalmic Res."},{"key":"2021111608021201600_B30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.cellsig.2012.10.015","article-title":"Cannabinoid receptor 1 suppresses transient receptor potential vanilloid 1-induced inflammatory responses to corneal injury","volume":"25","author":"Yang","journal-title":"Cell. Signal."},{"key":"2021111608021201600_B31","doi-asserted-by":"publisher","first-page":"7150","DOI":"10.1038\/ncomms8150","article-title":"TRPM8 is a neuronal osmosensor that regulates eye blinking in mice","volume":"6","author":"Quallo","year":"2015","journal-title":"Nat. Commun."},{"key":"2021111608021201600_B32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cellsig.2015.12.005","article-title":"3-Iodothyronamine increases transient receptor potential melastatin channel 8 (TRPM8) activity in immortalized human corneal epithelial cells","volume":"28","author":"Lucius","year":"2016","journal-title":"Cell. Signal."},{"key":"2021111608021201600_B33","doi-asserted-by":"publisher","first-page":"e7383","DOI":"10.1371\/journal.pone.0007383","article-title":"The contribution of TRPM8 and TRPA1 channels to cold allodynia and neuropathic pain","volume":"4","author":"Caspani","year":"2009","journal-title":"PLoS One"},{"key":"2021111608021201600_B34","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/j.1532-2149.2014.494.x","article-title":"Somatosensory and vasomotor manifestations of individual and combined stimulation of TRPM8 and TRPA1 using topical L-menthol and trans-cinnamaldehyde in healthy volunteers","volume":"18","author":"Olsen","year":"2014","journal-title":"Eur. J. Pain."},{"key":"2021111608021201600_B35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/000163502753509455","article-title":"VRl- and VRL-l-like immunoreactivity in normal and injured trigeminal dental primary sensory neurons of the rat","volume":"60","author":"Stenholm","year":"2002","journal-title":"Acta Odontol. Scand."},{"key":"2021111608021201600_B36","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1097\/ICO.0000000000000602","article-title":"Transient receptor potential channels and corneal stromal inflammation","volume":"34","author":"Okada","year":"2015","journal-title":"Cornea"},{"key":"2021111608021201600_B37","first-page":"1507","article-title":"Differential expression and localization of transient receptor potential vanilloid 1 in rabbit and human eyes","volume":"28","author":"Mart\u00ednez-Garc\u00eda","year":"2013","journal-title":"Histol. Histopathol."},{"key":"2021111608021201600_B38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2174\/1874467210801030255","article-title":"TRPV1: on the road to pain relief","volume":"1","author":"Jara-Oseguera","year":"2008","journal-title":"Curr. Mol. Pharmacol."},{"key":"2021111608021201600_B39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0083-6729(09)81015-7","article-title":"Anandamide and the vanilloid receptor (TRPV1)","volume":"81","author":"T\u00f3th","year":"2009","journal-title":"Vitam. Horm."},{"key":"2021111608021201600_B40","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1016\/S1542-0124(12)70256-2","article-title":"Neurogenic inflammation: a first line of defense for the ocular surface","volume":"3","author":"Beuerman","year":"2005","journal-title":"Ocul. Surf."},{"key":"2021111608021201600_B41","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1002\/jcp.24398","article-title":"The cellular mechanisms of dry eye: From pathogenesis to treatment","volume":"228","author":"Mantelli","year":"2013","journal-title":"J. Cell Physiol."},{"key":"2021111608021201600_B42","first-page":"671","article-title":"Substance P immunoreactive nerves in the human cornea and iris","volume":"23","author":"Tervo","year":"1982","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2021111608021201600_B43","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1001\/archopht.1985.01050080119031","article-title":"Substance P-like immunoreactive nerves in the human eye","volume":"103","author":"Stone","year":"1985","journal-title":"Arch. Ophthalmol."},{"key":"2021111608021201600_B44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/cne.903130110","article-title":"Calcitonin gene-related peptide and corneal innervation: a developmental study in the rat","volume":"313","author":"Jones","year":"1991","journal-title":"J. Comp. Neurol."},{"key":"2021111608021201600_B45","first-page":"2242","article-title":"Morphology and neurochemistry of canine corneal innervation","volume":"42","author":"Marfurt","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2021111608021201600_B46","first-page":"S28","article-title":"Distribution of substance P (SP) and calcitonin gene related peptide (GGRP) in human corneal nerves","volume":"42","author":"M\u00fcller","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2021111608021201600_B47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.npep.2016.06.001","article-title":"Interaction of calcitonin gene related peptide (CGRP) and substance P (SP) in human skin","volume":"59","author":"Schlereth","year":"2016","journal-title":"Neuropeptides"},{"key":"2021111608021201600_B48","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S1357-2725(01)00031-0","article-title":"Substance p","volume":"33","author":"Harrison","year":"2001","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2021111608021201600_B49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0079-6123(06)61007-8","article-title":"Substance P in traumatic brain injury","volume":"161","author":"Donkin","year":"2007","journal-title":"Prog. Brain Res."},{"key":"2021111608021201600_B50","first-page":"1","article-title":"Diagnosis and classification of neuropathic pain epidemiology and impact of neuropathic pain","volume":"XVIII","author":"IASP","year":"2010","journal-title":"Pain Medicine"},{"key":"2021111608021201600_B51","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ajo.2011.11.030","article-title":"Impact of ocular surface symptoms on quality of life in a United States veterans affairs population","volume":"153","author":"Pouyeh","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"2021111608021201600_B52","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/eye.2014.263","article-title":"Neuropathic ocular pain: an important yet underevaluated feature of dry eye","volume":"29","author":"Galor","year":"2015","journal-title":"Eye"},{"key":"2021111608021201600_B53","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.ophtha.2017.08.004","article-title":"Neuropathic corneal pain: approaches for management","volume":"124","author":"Dieckmann","year":"2017","journal-title":"Ophthalmology"},{"key":"2021111608021201600_B54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/bja\/87.1.12","article-title":"Mechanisms of neuropathic pain","volume":"87","author":"Bridges","year":"2001","journal-title":"Br. J. Anaesth."},{"key":"2021111608021201600_B55","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1474-4422(14)70102-4","article-title":"Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms","volume":"13","author":"Jensen","year":"2014","journal-title":"Lancet Neurol."},{"key":"2021111608021201600_B56","article-title":"Survey of systems involved in nociceptive processing","volume-title":"Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches","author":"Yaksh","year":"2014"},{"key":"2021111608021201600_B57","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0304-3959(83)90164-1","article-title":"Sensory afferent impulses originate from dorsal root ganglia as well as the periphery in normal and nerve injured rats","volume":"17","author":"Wall","year":"1983","journal-title":"Pain"},{"key":"2021111608021201600_B58","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780199563678.001.0001","volume-title":"Neuropathic Pain","author":"Bennett","year":"2010"},{"key":"2021111608021201600_B59","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2217\/pmt.14.38","article-title":"A practical approach to ocular pain for the non-ophthalmologist","volume":"4","author":"Waldman","year":"2014","journal-title":"Pain Manag."},{"key":"2021111608021201600_B60","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol."},{"key":"2021111608021201600_B61","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2147\/OPTH.S5555","article-title":"Etiology, prevalence, and treatment of dry eye disease","volume":"3","author":"Gayton","year":"2009","journal-title":"Clin. Ophthalmol."},{"key":"2021111608021201600_B62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtos.2017.10.001","article-title":"Neuropathic pain and dry eye","volume":"16","author":"Galor","year":"2018","journal-title":"Ocul. Surf."},{"key":"2021111608021201600_B63","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3109\/02713689609008906","article-title":"Tear meniscus measurement in the diagnosis of dry eye","volume":"15","author":"Mainstone","year":"1996","journal-title":"Curr. Eye Res."},{"key":"2021111608021201600_B64","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/01.ico.0000133997.07144.9e","article-title":"The lack of association between signs and symptoms in patients with dry eye disease","volume":"23","author":"Nichols","year":"2004","journal-title":"Cornea"},{"key":"2021111608021201600_B65","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/nm.2264","article-title":"Ocular surface wetness is regulated by TRPM8-dependent cold thermoreceptors of the cornea","volume":"16","author":"Parra","year":"2010","journal-title":"Nat. Med."},{"key":"2021111608021201600_B66","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1152\/jn.00657.2011","article-title":"Ocular dryness excites two classes of corneal afferent neurons implicated in basal tearing in rats: involvement of transient receptor potential channels","volume":"107","author":"Hirata","year":"2012","journal-title":"J. Neurophysiol."},{"key":"2021111608021201600_B67","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.brainresrev.2005.11.004","article-title":"Immune and inflammatory mechanisms in neuropathic pain","volume":"51","author":"Moalem","year":"2006","journal-title":"Brain Res. Rev."},{"key":"2021111608021201600_B68","first-page":"125","article-title":"Neuropathic pain: role of inflammation, immune response, and ion channel activity in central injury mechanisms","volume":"19","author":"Schomberg","year":"2012","journal-title":"Ann. Neurosci."},{"key":"2021111608021201600_B69","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/bja\/aet128","article-title":"Neuroinflammation and the generation of neuropathic pain","volume":"111","author":"Ellis","year":"2013","journal-title":"Br. J. Anaesth."},{"key":"2021111608021201600_B70","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/B978-0-444-52901-5.00015-0","article-title":"Neuropathic pain","volume":"110","author":"Kerstman","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"2021111608021201600_B71","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/j.pain.0000000000001122","article-title":"Inflammation in the pathophysiology of neuropathic pain","volume":"159","author":"Sommer","year":"2018","journal-title":"Pain"},{"key":"2021111608021201600_B72","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S0002-9394(03)00202-2","article-title":"Case-control study of endophthalmitis after cataract surgery comparing scleral tunnel and clear corneal wounds","volume":"136","author":"Cooper","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"2021111608021201600_B73","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/eye.2008.382","article-title":"Ocular immune privilege","volume":"23","author":"Taylor","year":"2009","journal-title":"Eye"},{"key":"2021111608021201600_B74","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/196094","article-title":"Role of inflammation in endophthalmitis","volume":"2012","author":"Vallejo-Garcia","year":"2012","journal-title":"Mediators Inflamm."},{"key":"2021111608021201600_B75","first-page":"3234","article-title":"Immunomorphologic studies of macrophages and MHC class II-positive dendritic cells in the iris and ciliary body of the rat, mouse, and human eye","volume":"35","author":"McMenamin","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2021111608021201600_B76","doi-asserted-by":"publisher","first-page":"e61799","DOI":"10.1371\/journal.pone.0061799","article-title":"Macrophage depletion impairs corneal wound healing after autologous transplantation in mice","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"2021111608021201600_B77","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2147\/OPTH.S1067","article-title":"Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension","volume":"2","author":"Gaynes","year":"2008","journal-title":"Clin. Ophthalmol."},{"key":"2021111608021201600_B78","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.survophthal.2009.07.005","article-title":"Nonsteroidal anti-inflammatory drugs in ophthalmology","volume":"55","author":"Kim","year":"2010","journal-title":"Surv. Ophthalmol."},{"key":"2021111608021201600_B79","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/1060028015574593","article-title":"Comparing the efficacy of ophthalmic NSAIDs in common indications: a literature review to support cost-effective prescribing","volume":"49","author":"Wilson","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"2021111608021201600_B80","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/j.apmr.2007.12.003","article-title":"Chronic pain and opiates: balancing pain control and risks in long-term opioid treatment","volume":"89","author":"Gallagher","year":"2008","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"2021111608021201600_B81","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd3624","article-title":"The neuropathic pain market","volume":"11","author":"Nightingale","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021111608021201600_B82","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.jcrs.2007.06.043","article-title":"Nepafenac-associated corneal melt","volume":"33","author":"Wolf","year":"2007","journal-title":"J. Cataract Refract Surg."},{"key":"2021111608021201600_B83","doi-asserted-by":"publisher","first-page":"789623","DOI":"10.1155\/2012\/789623","article-title":"Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate","volume":"2012","author":"Comstock","year":"2012","journal-title":"Int. J. Inflam."},{"key":"2021111608021201600_B84","volume-title":"Ophthalmic Medications and Pharmacology","author":"Duvall","year":"2006","edition":"2nd ed."},{"key":"2021111608021201600_B85","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1517\/14656566.2013.772982","article-title":"Pharmacotherapy of scleritis: current paradigms and future directions","volume":"14","author":"Beardsley","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"2021111608021201600_B86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003495-199600525-00004","article-title":"The mechanisms of action of NSAIDs in analgesia","volume":"52","author":"Cashman","year":"1996","journal-title":"Drugs"},{"key":"2021111608021201600_B87","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1016\/S0002-9343(97)00203-9","article-title":"Mechanism of action of nonsteroidal anti-inflammatory drugs","volume":"104","author":"Vane","year":"1998","journal-title":"Am. J. Med."},{"key":"2021111608021201600_B88","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.2165\/00002018-200225040-00002","article-title":"Topical non-steroidal anti-inflammatory drugs for ophthalmic use","volume":"25","author":"Gaynes","year":"2002","journal-title":"Drug Saf."},{"key":"2021111608021201600_B89","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev.pa.33.040193.002251","article-title":"Renal toxicity of the non-steroidal anti-inflammatory drugs","volume":"33","author":"Murray","year":"1993","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2021111608021201600_B90","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/gut.52.4.600","article-title":"Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors","volume":"52","author":"Hawkey","year":"2003","journal-title":"Gut"},{"key":"2021111608021201600_B91","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"2021111608021201600_B92","first-page":"11","article-title":"Paracetamol: mechanism of action, applications and safety concern","volume":"71","author":"J\u00f3\u017awiak-Bebenista","year":"2014","journal-title":"Acta Pol. Pharm."},{"key":"2021111608021201600_B93","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1155\/2014\/754693","article-title":"Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society","volume":"19","author":"Moulin","year":"2014","journal-title":"Pain Res. Manag."},{"key":"2021111608021201600_B94","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","article-title":"Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens","volume":"115","author":"Freynhagen","year":"2005","journal-title":"Pain"},{"key":"2021111608021201600_B95","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.brainres.2005.12.084","article-title":"Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice","volume":"1075","author":"Bian","year":"2006","journal-title":"Brain Res."},{"key":"2021111608021201600_B96","doi-asserted-by":"publisher","first-page":"8494","DOI":"10.1523\/JNEUROSCI.2982-04.2004","article-title":"Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia","volume":"24","author":"Li","year":"2004","journal-title":"J. Neurosci."},{"key":"2021111608021201600_B97","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.nurt.2009.08.002","article-title":"Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside","volume":"6","author":"Rahn","year":"2009","journal-title":"Neurotherapeutics"},{"key":"2021111608021201600_B98","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1365-2125.2011.03970.x","article-title":"Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials","volume":"72","author":"Lynch","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2021111608021201600_B99","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5055\/jom.2009.0016","article-title":"Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions","volume":"5","author":"Aggarwal","year":"2009","journal-title":"J. Opioid. Manag."},{"key":"2021111608021201600_B100","doi-asserted-by":"publisher","first-page":"110","DOI":"10.9740\/mhc.2018.05.110","article-title":"Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis","volume":"8","author":"Bellnier","year":"2018","journal-title":"Ment. Health Clin."},{"key":"2021111608021201600_B101","first-page":"5","article-title":"Plant-based cannabinoids for the treatment of chronic neuropathic pain","volume":"2018","author":"Casey","year":"2018","journal-title":"Medicines"},{"key":"2021111608021201600_B102","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.hoc.2018.01.005","article-title":"Cancer-related neuropathic pain: review and selective topics","volume":"32","author":"Davis","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"2021111608021201600_B103","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.coph.2018.03.012","article-title":"Cannabis and joints: scientific evidence for the alleviation of osteoarthritis pain by cannabinoids","volume":"40","author":"O\u2019Brien","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"2021111608021201600_B104","doi-asserted-by":"publisher","first-page":"9388","DOI":"10.1073\/pnas.0409641102","article-title":"Altering cannabinoid signaling during development disrupts neuronal activity","volume":"102","author":"Bernard","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111608021201600_B105","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.phrs.2009.03.019","article-title":"Endocannabinoids and immune regulation","volume":"60","author":"Pandey","year":"2009","journal-title":"Pharmacol. Res."},{"key":"2021111608021201600_B106","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/febs.12260","article-title":"Modulating the endocannabinoid system in human health and disease\u2013successes and failures","volume":"280","author":"Pacher","year":"2013","journal-title":"FEBS J."},{"key":"2021111608021201600_B107","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cmet.2013.03.001","article-title":"The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders","volume":"17","author":"Silvestri","year":"2013","journal-title":"Cell Metab."},{"key":"2021111608021201600_B108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-20825-1_1","article-title":"Endocannabinoids and their pharmacological actions","volume":"231","author":"Pertwee","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"key":"2021111608021201600_B109","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrcardio.2017.130","article-title":"Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly","volume":"15","author":"Pacher","year":"2018","journal-title":"Nat Rev. Cardiol."},{"key":"2021111608021201600_B110","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrn3811","article-title":"Early phytocannabinoid chemistry to endocannabinoids and beyond","volume":"15","author":"Mechoulam","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"2021111608021201600_B111","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, structure, and partial synthesis of an active constituent of Hashish","volume":"86","author":"Gaoni","year":"1964","journal-title":"J. Am. Chem. Soc."},{"key":"2021111608021201600_B112","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"2021111608021201600_B113","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","article-title":"Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors","volume":"50","author":"Mechoulam","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"2021111608021201600_B114","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/nrgastro.2013.245","article-title":"Patients with IBD find symptom relief in FAAH: fatty acid amide hydrolase; MAGL: monoacylglycerol lipase","volume":"11","author":"Schicho","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2021111608021201600_B115","doi-asserted-by":"publisher","first-page":"561e4","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"2021111608021201600_B116","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"2021111608021201600_B117","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology: XXVII. Classification Of Cannabinoid Receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"2021111608021201600_B118","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2174\/092986710790980050","article-title":"Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists","volume":"17","author":"Pertwee","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"2021111608021201600_B119","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/sj.bjp.0707456","article-title":"The complications of promiscuity: endocannabinoid action and metabolism","volume":"152","author":"Alexander","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B120","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/npp.2017.130","article-title":"Circulating endocannabinoids: from whence do they come and where are they going?","volume":"43","author":"Hillard","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"2021111608021201600_B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.irn.2015.10.001","article-title":"The endocannabinoid signaling system in the CNS: a primer","volume":"125","author":"Hillard","year":"2015","journal-title":"Int. Rev. Neurobiol."},{"key":"2021111608021201600_B122","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1006\/nbdi.1998.0221","article-title":"Endogenous cannabinoid signaling","volume":"5","author":"Piomelli","year":"1998","journal-title":"Neurobiol. Dis."},{"key":"2021111608021201600_B123","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/42015","article-title":"A second endogenous cannabinoid that modulates long-term potentiation","volume":"388","author":"Stella","year":"1997","journal-title":"Nature"},{"key":"2021111608021201600_B124","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0006-2952(98)00314-1","article-title":"Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors","volume":"57","author":"Goparaju","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"2021111608021201600_B125","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00109-008-0359-6","article-title":"Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors","volume":"86","author":"Storr","year":"2008","journal-title":"J. Mol. Med."},{"key":"2021111608021201600_B126","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/384083a0","article-title":"Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides","volume":"384","author":"Cravatt","year":"1996","journal-title":"Nature"},{"key":"2021111608021201600_B127","doi-asserted-by":"publisher","first-page":"9371","DOI":"10.1073\/pnas.161191698","article-title":"Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase","volume":"98","author":"Cravatt","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111608021201600_B128","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.chembiol.2007.11.006","article-title":"A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol","volume":"14","author":"Blankman","year":"2007","journal-title":"Chem. Biol."},{"key":"2021111608021201600_B129","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1208\/s12248-009-9084-5","article-title":"Cannabinoids, endocannabinoids, and related analogs in inflammation","volume":"11","author":"Burstein","year":"2009","journal-title":"AAPS J."},{"key":"2021111608021201600_B130","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1748-1716.2011.02280.x","article-title":"The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors","volume":"204","author":"Savinainen","year":"2012","journal-title":"Acta Physiol."},{"key":"2021111608021201600_B131","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.bbalip.2014.12.015","article-title":"Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases","volume":"1851","author":"Urquhart","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111608021201600_B132","doi-asserted-by":"publisher","first-page":"12856","DOI":"10.1074\/jbc.M008555200","article-title":"The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism","volume":"276","author":"De Petrocellis","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2021111608021201600_B133","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/sj.bjp.0705468","article-title":"Cellular accumulation of anandamide: consensus and controversy","volume":"140","author":"Hillard","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B134","doi-asserted-by":"publisher","first-page":"17852","DOI":"10.1073\/pnas.0507470102","article-title":"Identification of a high-affinity binding site involved in the transport of endocannabinoids","volume":"102","author":"Moore","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111608021201600_B135","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/187152709789824660","article-title":"The endocannabinoid system and pain","volume":"8","author":"Guindon","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"2021111608021201600_B136","doi-asserted-by":"publisher","first-page":"34660","DOI":"10.1074\/jbc.M112.373241","article-title":"Evidence for bidirectional endocannabinoid transport across cell membranes","volume":"287","author":"Chicca","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2021111608021201600_B137","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1111\/febs.12212","article-title":"Transport of endocannabinoids across the plasma membrane and within the cell","volume":"280","author":"Fowler","year":"2013","journal-title":"FEBS J."},{"key":"2021111608021201600_B138","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021111608021201600_B139","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","article-title":"Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations","volume":"232","author":"Gali\u00e8gue","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"2021111608021201600_B140","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.tips.2015.02.008","article-title":"Endocannabinoid signaling at the periphery: 50 years after THC","volume":"36","author":"Maccarrone","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"2021111608021201600_B141","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science"},{"key":"2021111608021201600_B142","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","article-title":"Determination and characterization of a cannabinoid receptor in rat brain","volume":"34","author":"Devane","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"2021111608021201600_B143","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/3-540-26573-2_2","article-title":"Cannabinoid receptor signaling","volume":"168","author":"Howlett","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"key":"2021111608021201600_B144","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1189\/jlb.0307159","article-title":"Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis","volume":"82","author":"Xu","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"2021111608021201600_B145","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/sj.bjp.0707486","article-title":"Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation","volume":"153","author":"Wright","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B146","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1111\/bph.12545","article-title":"Anti-inflammatory effects of cannabinoid CB2 receptor activation in endotoxin-induced uveitis","volume":"171","author":"Toguri","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B147","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3233\/CH-151996","article-title":"Cannabinoid 2 receptor activation reduces leukocyte adhesion and improves capillary perfusion in the iridial microvasculature during systemic inflammation","volume":"61","author":"Toguri","year":"2015","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"2021111608021201600_B148","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pnpbp.2015.03.017","article-title":"Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson\u2019s disease","volume":"64","author":"G\u00f3mez-G\u00e1lvez","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"2021111608021201600_B149","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1476-5381.2012.02042.x","article-title":"Targeting cannabinoid receptor CB2 in cardiovascular disorders: Promises and controversies","volume":"167","author":"Steffens","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B150","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11481-013-9445-9","article-title":"Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation","volume":"8","author":"Rom","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"2021111608021201600_B151","first-page":"2442","article-title":"Localization of cannabinoid CB1 receptors in the human anterior eye and retina","volume":"40","author":"Straiker","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2021111608021201600_B152","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1046\/j.1460-9568.2000.01027.x","article-title":"The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein","volume":"12","author":"Porcella","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"2021111608021201600_B153","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0014-2999(01)01438-8","article-title":"Cannabinoid CB1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues","volume":"431","author":"Stamer","year":"2001","journal-title":"Eu. J. Pharmacol."},{"key":"2021111608021201600_B154","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.preteyeres.2008.07.002","article-title":"Endocannabinoids in the retina: from marijuana to neuroprotection","volume":"27","author":"Yazulla","year":"2008","journal-title":"Prog. Retin. Eye Res."},{"key":"2021111608021201600_B155","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1002\/cne.23333","article-title":"M\u00fcller cells express the cannabinoid CB2 receptor in the vervet monkey retina","volume":"521","author":"Bouskila","year":"2013","journal-title":"J. Comp. Neurol."},{"key":"2021111608021201600_B156","doi-asserted-by":"publisher","first-page":"1253245","DOI":"10.1155\/2016\/1253245","article-title":"Cannabinoid Receptors CB1 and CB2 modulate the electroretinographic waves in vervet monkeys","volume":"2016","author":"Bouskila","year":"2016","journal-title":"Neural Plast."},{"key":"2021111608021201600_B157","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fphar.2016.00304","article-title":"Turning down the thermostat: modulating the endocannabinoid system in ocular inflammation and pain","volume":"7","author":"Toguri","year":"2016","journal-title":"Front. Pharmacol."},{"key":"2021111608021201600_B158","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.bbrc.2005.03.095","article-title":"Finding of endocannabinoids in human eye tissues: implications for glaucoma","volume":"330","author":"Chen","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111608021201600_B159","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1002\/cne.22429","article-title":"Architecture of cannabinoid signaling in mouse retina","volume":"518","author":"Hu","year":"2010","journal-title":"J. Comp. Neurol."},{"key":"2021111608021201600_B160","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.neuroscience.2011.11.041","article-title":"Expression and localization of the cannabinoid receptor type 1 and the enzyme fatty acid amide hydrolase in the retina of vervet monkeys","volume":"202","author":"Bouskila","year":"2012","journal-title":"Neuroscience"},{"key":"2021111608021201600_B161","doi-asserted-by":"publisher","first-page":"8079","DOI":"10.1167\/iovs.13-12514","article-title":"Roles of cannabinoid receptors type 1 and 2 on the retinal function of adult mice","volume":"54","author":"C\u00e9cyre","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2021111608021201600_B162","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00210-013-0930-8","article-title":"Evaluation of the specificity of antibodies raised against cannabinoid receptor type 2 in the mouse retina","volume":"387","author":"C\u00e9cyre","year":"2014","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"2021111608021201600_B163","doi-asserted-by":"publisher","first-page":"9247057","DOI":"10.1155\/2016\/9247057","article-title":"Expression and function of the endocannabinoid system in the retina and the visual brain","volume":"2016","author":"Bouchard","year":"2016","journal-title":"Neural Plast."},{"key":"2021111608021201600_B164","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1515\/jbcpp-2015-0065","article-title":"Seeing over the horizon: targeting the endocannabinoid system for the treatment of ocular disease","volume":"27","author":"Cairns","year":"2016","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"2021111608021201600_B165","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2018.09.004","article-title":"Inflammation and CB2 signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eye","author":"Toguri","year":"2018","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"2021111608021201600_B166","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.tips.2007.10.006","article-title":"Allosterism and cannabinoid CB(1) receptors: the shape of things to come","volume":"28","author":"Ross","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"2021111608021201600_B167","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrd4052","article-title":"Emerging paradigms in GPCR allostery: implications for drug discovery","volume":"12","author":"Wootten","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021111608021201600_B168","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.tips.2017.05.010","article-title":"Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs","volume":"38","author":"Congr\u00e8ve","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"2021111608021201600_B169","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/03602532.2018.1428341","article-title":"The future of type 1 cannabinoid receptor allosteric ligands","volume":"50","author":"Alaverdashvili","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"2021111608021201600_B170","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/03602532.2018.1428342","article-title":"Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity","volume":"50","author":"Dopart","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"2021111608021201600_B171","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lfs.2018.04.054","article-title":"Enhanced endocannabinoid tone as a potential target of pharmacotherapy","volume":"204","author":"Toczek","year":"2018","journal-title":"Life Sci."},{"key":"2021111608021201600_B172","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1167\/iovs.14-15675","article-title":"Cannabinoid-induced chemotaxis in bovine corneal epithelial cells","volume":"56","author":"Murataeva","year":"2015","journal-title":"Invest. Opthalmol. Vis. Sci."},{"key":"2021111608021201600_B173","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2174\/157015907780866884","article-title":"The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration","volume":"5","author":"Ashton","year":"2007","journal-title":"Curr. Neuropharmacol."},{"key":"2021111608021201600_B174","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/0301-4738.58468","article-title":"Current approach in diagnosis and management of anterior uveitis","volume":"58","author":"Agrawal","year":"2010","journal-title":"Indian J. Ophthalmol."},{"key":"2021111608021201600_B175","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/jop.2011.0049","article-title":"A cannabinoid ligand, anandamide, exacerbates endotoxin-induced uveitis in rabbits","volume":"27","author":"Altinsoy","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2021111608021201600_B176","first-page":"3e18","article-title":"Proliferative vitreoretinopathy: an overview. Surv.","volume":"43","author":"Pastor","year":"1998","journal-title":"Ophthalmol."},{"key":"2021111608021201600_B177","doi-asserted-by":"publisher","first-page":"14228","DOI":"10.1073\/pnas.96.25.14228","article-title":"HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor","volume":"96","author":"Hanu\u0161","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111608021201600_B178","doi-asserted-by":"publisher","first-page":"13958","DOI":"10.1038\/ncomms13958","article-title":"Cannabinoid CB receptor ligand profiling reveals biased signalling and off-target activity","volume":"8","author":"Soethoudt","year":"2017","journal-title":"Nat. Commun."},{"key":"2021111608021201600_B179","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuropharm.2016.08.030","article-title":"Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy","volume":"113, Part B","author":"Szczesniak","year":"2017","journal-title":"Neuropharmacology"},{"key":"2021111608021201600_B180","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0304-3959(02)00271-3","article-title":"Topical cannabinoid agonist, WIN55,212-2, reduces cornea-evoked trigeminal brainstem activity in the rat","volume":"99","author":"Bereiter","year":"2002","journal-title":"Pain"},{"key":"2021111608021201600_B181","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1089\/can.2017.0041","article-title":"The Cannabinoids \u22068THC, CBD, and HU-308 act via distinct receptors to reduce corneal pain and inflammation","volume":"3","author":"Thapa","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"2021111608021201600_B182","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neulet.2013.06.066","article-title":"CB1 cannabinoid receptor agonist prevents NGF-induced sensitization of TRPV1 in sensory neurons","volume":"551","author":"McDowell","year":"2013","journal-title":"Neurosci. Lett."},{"key":"2021111608021201600_B183","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1167\/iovs.07-1537","article-title":"N-Arachidonyletha- nolamide-induced increase in aqueous humor outflow facility","volume":"49","author":"Njie","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2021111608021201600_B184","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1124\/jpet.111.185769","article-title":"Indirect sympatholytic actions at beta-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists","volume":"339","author":"Hudson","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021111608021201600_B185","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1080\/17460441.2016.1245289","article-title":"Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target","volume":"11","author":"Janero","year":"2016","journal-title":"Exp. Opin. Drug Discov."},{"key":"2021111608021201600_B186","doi-asserted-by":"publisher","first-page":"8286","DOI":"10.1021\/bi400842k","article-title":"The membrane proximal region of the cannabinoid receptor CB1 N-terminus can allosterically modulate ligand affinity","volume":"52","author":"Fay","year":"2013","journal-title":"Biochemistry"},{"key":"2021111608021201600_B187","doi-asserted-by":"publisher","first-page":"5828","DOI":"10.1074\/jbc.M113.478495","article-title":"Allosteric modulation of a cannabinoid G protein-coupled receptor binding site elucidation and relationship to G protein signaling","volume":"289","author":"Shore","year":"2014","journal-title":"J. Biol. Chem."},{"key":"2021111608021201600_B188","doi-asserted-by":"publisher","first-page":"15453","DOI":"10.1038\/srep15453","article-title":"Endogenous vs exogenous allosteric modulators in GPCRs: a dispute for shuttling CB1 among different membrane microenvironments","volume":"5","author":"Stornaiuolo","year":"2015","journal-title":"Sci. Rep."},{"key":"2021111608021201600_B189","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2016.10.004","article-title":"Crystal structure of the human cannabinoid receptor CB1","volume":"167","author":"Hua","year":"2016","journal-title":"Cell"},{"key":"2021111608021201600_B190","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nature20613","article-title":"High-resolution crystal structure of the human CB1 cannabinoid receptor","volume":"540","author":"Shao","year":"2016","journal-title":"Nature"},{"key":"2021111608021201600_B191","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/nature23272","article-title":"Crystal structures of agonist-bound human cannabinoid receptor CB1","volume":"547","author":"Hua","year":"2017","journal-title":"Nature"},{"key":"2021111608021201600_B192","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/med.21418","article-title":"Allosteric modulation: an alternate approach targeting the cannabinoid CB1 receptor","volume":"37","author":"Nguyen","year":"2016","journal-title":"Med. Res. Rev."},{"key":"2021111608021201600_B193","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/bph.12329","article-title":"Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action","volume":"170","author":"Cawston","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B194","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1124\/mol.115.099192","article-title":"Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor","volume":"88","author":"Khajehali","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"2021111608021201600_B195","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1124\/mol.115.101980","article-title":"Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease","volume":"89","author":"Laprairie","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"2021111608021201600_B196","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coph.2016.10.005","article-title":"Cannabinoid receptor ligand bias: implications in the central nervous system","volume":"32","author":"Laprairie","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"2021111608021201600_B197","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/jhet.2861","article-title":"Microwave-accelerated conjugate addition of 2-arylindoles to substituted b-nitrostyrenes in the presence of ammonium trifluoroacetate: an efficient approach for the synthesis of a novel class of CB1 cannabinoid receptor allosteric modulators","volume":"54","author":"Kulkarni","year":"2017","journal-title":"J. Heterocycl. Chem."},{"key":"2021111608021201600_B198","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1124\/mol.105.016162","article-title":"Allosteric modulation of the cannabinoid CB1 receptor","volume":"68","author":"Price","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"2021111608021201600_B199","doi-asserted-by":"publisher","first-page":"12070","DOI":"10.1074\/jbc.M111.316463","article-title":"Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1\/2 kinase activation","volume":"287","author":"Ahn","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2021111608021201600_B200","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1476-5381.2010.00870.x","article-title":"Regional enhancement of cannabinoid CB receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure","volume":"161","author":"Burston","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B201","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/TCRM.S1928","article-title":"Cannabinoids in the management of difficult to treat pain","volume":"4","author":"Russo","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"2021111608021201600_B202","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1021\/acschemneuro.6b00310","article-title":"Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor","volume":"8","author":"Laprairie","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"2021111608021201600_B203","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1089\/jop.2017.0037","article-title":"The in vivo effects of the CB-positive allosteric modulator GAT229 on intraocular pressure in ocular normotensive and hypertensive mice","volume":"33","author":"Cairns","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2021111608021201600_B204","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nrd2553","article-title":"Targeting the endocannabinoid system: to enhance or reduce?","volume":"7","author":"Di Marzo","year":"2008","journal-title":"Nat. Rev. Drug. Discov."},{"key":"2021111608021201600_B205","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1098\/rstb.2011.0390","article-title":"Dynamic changes to the endocannabinoid system in models of chronic pain","volume":"367","author":"Sagar","year":"2012","journal-title":"Philos. Trans. Royal Soc. B"},{"key":"2021111608021201600_B206","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.prostaglandins.2013.02.002","article-title":"Endogenous cannabinoids revisited: a biochemistry perspective","volume":"102-103","author":"Fonseca","year":"2013","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"2021111608021201600_B207","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/bph.12411","article-title":"Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS","volume":"171","author":"Murataeva","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B208","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/cbdv.200790144","article-title":"History of cannabis and its preparations in saga, science, and sobriquet","volume":"4","author":"Russo","year":"2007","journal-title":"Chem. Biodivers."},{"key":"2021111608021201600_B209","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1124\/jpet.109.155465","article-title":"Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain","volume":"330","author":"Kinsey","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021111608021201600_B210","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jpain.2010.04.001","article-title":"Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms","volume":"11","author":"Kinsey","year":"2010","journal-title":"J. Pain"},{"key":"2021111608021201600_B211","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1111\/bph.13970","article-title":"Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats","volume":"174","author":"Zubrzycki","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B212","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbr.2018.06.030","article-title":"FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behaviour in female rats","volume":"353","author":"Flannery","year":"2018","journal-title":"Behav. Brain. Res."},{"key":"2021111608021201600_B213","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000003563","article-title":"Inhibition of fatty acid amide hydrolase improves depressive-like behaviors independent of its peripheral antinociceptive effects in a rat model of neuropathic pain","author":"Jiang","year":"2018","journal-title":"Anesth. Analg."},{"key":"2021111608021201600_B214","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neuropharm.2013.04.018","article-title":"The fatty acid amide hydrolase inhibitor, URB597, promotes retinal ganglion cell neuroprotection in a rat model of optic nerve axotomy","volume":"72C","author":"Slusar","year":"2013","journal-title":"Neuropharmacology"},{"key":"2021111608021201600_B215","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy057","article-title":"Adult cellular neuroadaptations induced by adolescent THC exposure in female rats are rescued by enhancing anandamide signaling","author":"Cuccurazzu","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"2021111608021201600_B216","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1527-3458.2006.00021.x","article-title":"Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597)","volume":"12","author":"Piomelli","year":"2006","journal-title":"CNS Drug Rev."},{"key":"2021111608021201600_B217","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/sj.bjp.0706510","article-title":"Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models","volume":"147","author":"Jayamanne","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B218","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13075-017-1313-1","article-title":"Early blockade of joint inflammation with a fatty acid amide hydrolase inhibitor decreases end-stage osteoarthritis pain and peripheral neuropathy in mice","volume":"19","author":"McDougall","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"2021111608021201600_B219","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/nn.2632","article-title":"Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism","volume":"13","author":"Clapper","year":"2010","journal-title":"Nat. Neurosci."},{"key":"2021111608021201600_B220","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1177\/0333102414566862","article-title":"Effects of peripheral FAAH blockade on NTG-induced hyperalgesia\u2013evaluation of URB937 in an animal model of migraine","volume":"35","author":"Greco","year":"2015","journal-title":"Cephalalgia"},{"key":"2021111608021201600_B221","doi-asserted-by":"publisher","DOI":"10.1177\/1744806916649192","article-title":"A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase","author":"Carey","year":"2016","journal-title":"Mol. Pain"},{"key":"2021111608021201600_B222","doi-asserted-by":"publisher","first-page":"498","DOI":"10.5414\/CP202687","article-title":"FAAH inhibitors in the limelight, but regrettably","volume":"54","author":"Mallet","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"2021111608021201600_B223","first-page":"191","article-title":"Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis\/chronic pelvic pain syndrome: an adaptive double-blind","volume":"103","author":"Wagenlehner","year":"2017","journal-title":"Randomized Controlled Trial. Urol."},{"key":"2021111608021201600_B224","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.pain.2012.04.020","article-title":"An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee","volume":"153","author":"Huggins","year":"2012","journal-title":"Pain"},{"key":"2021111608021201600_B225","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1056\/NEJMoa1604221","article-title":"Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase","volume":"375","author":"Kerbrat","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2021111608021201600_B226","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aaf7497","article-title":"Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474","volume":"356","author":"van Esbroeck","year":"2017","journal-title":"Science"},{"key":"2021111608021201600_B227","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0014-2999(03)01856-9","article-title":"Cannabinoid pharmacological properties common to other centrally acting drugs","volume":"471","author":"Wiley","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"2021111608021201600_B228","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1124\/jpet.104.069401","article-title":"Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity","volume":"311","author":"Lichtman","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021111608021201600_B229","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nchembio.129","article-title":"Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects","volume":"5","author":"Long","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"2021111608021201600_B230","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0026-895X(24)26516-0","article-title":"Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide","volume":"57","author":"Gonsiorek","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"2021111608021201600_B231","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2334\/josnusd.17-0005","article-title":"Inhibition of 2-arachydonoylgycerol degradation attenuates orofacial neuropathic pain in trigeminal nerve-injured mice","volume":"60","author":"Kamimura","year":"2018","journal-title":"J. Oral Sci."},{"key":"2021111608021201600_B232","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.phrs.2010.03.007","article-title":"Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms","volume":"62","author":"Spradley","year":"2010","journal-title":"Pharmacol. Res."},{"key":"2021111608021201600_B233","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/j.1476-5381.2010.01192.x","article-title":"Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain","volume":"163","author":"Guindon","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B234","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/j.1476-5381.2012.02179.x","article-title":"Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat","volume":"167","author":"Woodhams","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B235","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.lfs.2012.06.020","article-title":"The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model","volume":"92","author":"Ghosh","year":"2013","journal-title":"Life Sci."},{"key":"2021111608021201600_B236","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.phrs.2012.10.013","article-title":"Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment","volume":"67","author":"Guindon","year":"2013","journal-title":"Pharmacol. Res."},{"key":"2021111608021201600_B237","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.phrs.2014.09.008","article-title":"JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy","volume":"90","author":"Khasabova","year":"2014","journal-title":"Pharmacol. Res."},{"key":"2021111608021201600_B238","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/bph.12298","article-title":"In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects","volume":"171","author":"Ignatowska-Jankowska","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B239","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1111\/bph.14055","article-title":"The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice","volume":"174","author":"Crowe","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B240","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1111\/bph.13012","article-title":"Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in mice","volume":"172","author":"Crowe","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"2021111608021201600_B241","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1167\/iovs.16-19356","article-title":"Harnessing the Endocannabinoid 2-arachidonoylglycerol to lower intraocular pressure in a murine model","volume":"257","author":"Miller","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Neuronal Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/neuronalsignal\/article-pdf\/doi\/10.1042\/NS20170144\/483448\/ns-2017-0144c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/neuronalsignal\/article-pdf\/doi\/10.1042\/NS20170144\/483448\/ns-2017-0144c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:08:43Z","timestamp":1775250523000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/neuronalsignal\/article\/2\/4\/NS20170144\/76939\/Potential-for-endocannabinoid-system-modulation-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":241,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12,21]]}},"URL":"https:\/\/doi.org\/10.1042\/ns20170144","relation":{},"ISSN":["2059-6553"],"issn-type":[{"value":"2059-6553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]},"article-number":"NS20170144"}}